Indian Pharmaceutical Alliance drops Sovaldi opposition
16-09-2015
suphakit73 / Shutterstock.com
India-based generic drug maker Natco Pharma has signed a non-exclusive licensing agreement with Gilead Sciences that allows Natco to make and sell generic versions of hepatitis C drugs including Sovaldi (sofosbuvir), it was announced yesterday (March 2).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Natco Pharma, Gilead Sciences, patent licensing agreement, Sovaldi, hepatitis C, patent, sofosbuvir